Masahiro Shinada

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Anti-tumor effect of a histone deacetylase inhibitor on canine malignant melanoma.

Anti-tumor effect of a histone deacetylase inhibitor on canine malignant melanoma.

Journal: The Journal of veterinary medical science
Published: December 07, 2025

Anti-tumor effect of proteasome inhibitor on canine urothelial carcinoma.

Anti-tumor effect of proteasome inhibitor on canine urothelial carcinoma.

Journal: The Journal of veterinary medical science
Published: July 21, 2024

Comprehensive Analysis of the Tumour Immune Microenvironment in Canine Urothelial Carcinoma Reveals Immunosuppressive Mechanisms Induced by the COX-Prostanoid Cascade.

Comprehensive Analysis of the Tumour Immune Microenvironment in Canine Urothelial Carcinoma Reveals Immunosuppressive Mechanisms Induced by the COX-Prostanoid Cascade.

Journal: Veterinary and comparative oncology
Published: April 05, 2024

Podoplanin promotes cell proliferation, survival, and migration of canine non-tonsillar squamous cell carcinoma.

Podoplanin promotes cell proliferation, survival, and migration of canine non-tonsillar squamous cell carcinoma.

Journal: The Journal of veterinary medical science
Published: August 06, 2023

Pan-tumour analysis of COX-2 expression in dogs.

Pan-tumour analysis of COX-2 expression in dogs.

Journal: Veterinary journal (London, England : 1997)
Published: June 08, 2023

Co-administration of JQ1, a bromodomain-containing protein 4 inhibitor, enhances the antitumor effect of combretastatin A4, a microtubule inhibitor, while attenuating its cardiotoxicity.

Co-administration of JQ1, a bromodomain-containing protein 4 inhibitor, enhances the antitumor effect of combretastatin A4, a microtubule inhibitor, while attenuating its cardiotoxicity.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: December 23, 2022

Podoplanin Drives Amoeboid Invasion in Canine and Human Mucosal Melanoma.

Podoplanin Drives Amoeboid Invasion in Canine and Human Mucosal Melanoma.

Journal: Molecular cancer research : MCR
Published: November 19, 2022

Detection of indoleamine 2,3-dioxygenase 1-expressing cells in canine normal and tumor tissues.

Detection of indoleamine 2,3-dioxygenase 1-expressing cells in canine normal and tumor tissues.

Journal: The Journal of veterinary medical science
Published: October 25, 2021

Expression of podoplanin in various types of feline tumor tissues.

Expression of podoplanin in various types of feline tumor tissues.

Journal: The Journal of veterinary medical science
Published: October 18, 2021

Author Correction: Aberrant expression of the COX2/PGE2 axis is induced by activation of the RAF/MEK/ERK pathway in BRAFV595E canine urothelial carcinoma.

Author Correction: Aberrant expression of the COX2/PGE2 axis is induced by activation of the RAF/MEK/ERK pathway in BRAFV595E canine urothelial carcinoma.

Journal: Scientific reports
Published: October 29, 2020

Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma.

Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma.

Journal: Cells
Published: September 29, 2020

Overexpression of human epidermal growth factor receptor 2 in canine primary lung cancer.

Overexpression of human epidermal growth factor receptor 2 in canine primary lung cancer.

Journal: The Journal of veterinary medical science
Published: April 07, 2020
Showing 1-12 of 18

Last Updated: 09/26/2026